RapidAI Raises $75M in Series C Funding
Summary
RapidAI, a San Mateo, CA-based developer of Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac and vascular diseases, raised $75m in Series C funding. The company intends to use the funds to support more disease states and go-to-market functions to accelerate growth in new regions and product verticals. Led by Karim Karti, CEO, RapidAI has built a comprehensive portfolio of stroke solutions, including Rapid NCCT Stroke – an FDA-cleared medical device to detect suspected intracranial hemorrhage (ICH) and large vessel occlusion (LVO) from non-contrast CT imaging. Rapid NCCT Stroke provides hospitals of all sizes and imaging capabilities access to imaging and decision support to address a wider population of patients. RapidAI has expanded into new disease states with FDA-cleared modules for cerebral aneurysm management and the identification and notification of suspected central pulmonary embolism.